Proper diagnosis and treatment of these diseases are of great importance, as early immunotherapeutic intervention can help reduce nerve injury.

Scientific Reports - Persistent neuromuscular disorders associated with changes in tibialis anterior and gastrocnemius lateralis muscle architecture in long-covid: an observational longitudinal study

Depression could be the presenting symptom in patients with transthyretin amyloid polyneuropathy (ATTR-PN), a study found.

OBJECTIVE. The clinical presentation, symptoms, and signs of neuropathy vary substantially. We determined whether painful neuropathic symptoms and distal s

Background: #diabetes-related lower extremity complications, such as foot ulceration and amputation, are on the rise, currently affecting nearly 131 million people worldwide. Methods for early detection of individuals at high risk remain elusive due to heterogeneity in clinical trajectories, barriers in patient-provider communication, and competing demands for clinician time during clinic visits. While data-driven diabetic polyneuropathy algorithms exist, high-performing, clinically useful tools to assess risk are needed to improve clinical care. Objective: Our objective was to develop an electronic medical record (EMR)-based machine learning algorithm that would predict lower extremity complications within 24 months of an initial diagnosis of diabetic polyneuropathy using rich longitudinal electronic health record data. Methods: We conducted a retrospective longitudinal cohort study to predict the risk of lower extremity complications within 24 months of an initial diagnosis of diabetic polyneuropathy. From an initial cohort of 468,162 individuals with at least one diagnosis of diabetic polyneuropathy at one of two multispecialty healthcare systems (based in northern California and Colorado) between April 2012 and December 2016, we created an analytic cohort of 48,209 adults with continuous enrollment, who were newly diagnosed with no evidence of end-of-life care. The outcome was any lower extremity complication, including foot ulceration, osteomyelitis, gangrene, and/or lower extremity amputation. We randomly split the outcomes into training (80%; n = 38,569) and testing (20%; n = 9,640) datasets. In the training dataset, we used Super Learner (SL), an ensemble learning method that employs cross-validation and combines multiple candidate risk predictors, including machine learning (ML) algorithms (e.g., random forest) or parametric (e.g., logistic) models into a single risk predictor. We evaluated the performance of the SL risk predictor in the testing dataset using area under the receiver operating characteristic curves (AUCs) to determine sensitivity versus specificity and negative predictive value, and to create a calibration plot (observed versus predicted risks) and alert thresholds. Results: Of the 48,209 individuals in the cohort, 2,327 developed a lower extremity complication during follow-up. The SL risk estimator exhibited good discrimination (area under the curve (AUC): 0.845 [95% Confidence Interval: 0.826, 0.863]) and calibration. A modified version of our SL algorithm, simplified to facilitate real-world adoption, had only slightly reduced discrimination (AUC: 0.817 [0.797, 0.837]). The modified version slightly outperformed the naïve logistic regression model (AUC: 0.804 [0.783, 0.825) in terms of precision gained relative to the frequency of alerts and number of patients that needed to be evaluated. Conclusions: We have built a machine learning-based risk estimator with the potential to improve clinical detection of diabetic patients at high risk for lower extremity complications at the time of an initial diabetic polyneuropathy diagnosis. The algorithm exhibited good discriminant validity and calibration using only data from the EMR. Additional research will be needed to identify optimal contexts and strategies for maximizing algorithmic fairness in both interpretation and deployment.

argenx (ARGX) has received European Commission approval for VYVGART SC (efgartigimod alfa) as a monotherapy for treating adult CIDP patients after prior corticosteroid or immunoglobulin treatment. This marks the first novel treatment mechanism for CIDP in over 30 years. The approval is based on the ADHERE trial, where 66.5% of patients showed clinical improvement and demonstrated a 61% reduction in relapse risk versus placebo. VYVGART SC, available as a vial or prefilled syringe, can be self-administered weekly with potential adjustment to bi-weekly dosing. The treatment specifically targets the neonatal Fc receptor (FcRn) and showed consistent safety results with previous studies. This approval applies to all 27 EU Member States plus Iceland, Liechtenstein, and Norway, representing a significant advancement for CIDP patients who often experience severe mobility issues and disability.

This has been a most remarkable week in CRISPR Therapeutics as momentum continues to build.  Bespoke therapeutic in 6 months First, the ...

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme’s proprietary recombinant …

In a groundbreaking study published in Nature Communications, a team of researchers has unveiled complex cellular and molecular landscapes associated with human polyneuropathies, revealing new insights into the pathophysiology of these debilitating nerve disorders. By leveraging advanced multi-omic technologies, the investigators, led by Heming, Börsch, and Wolbert, have uncovered a previously unrecognized role for perineurial hyperplasia and a distinctive subset of lipid-associated macrophages within affected peripheral nerves.